drugset / Trial / NCT05025293

Zoledronate Early to Hip Fracture Patients - Safe and Effective?

NCT05025293

RandomizedParallel-groupQuadruple-blindPrevention

Summary

To prevent hip fracture patients for having another fracture, secondary fracture preventing medication should be given as soon as possible. Zoledronate is the most efficient bisphosphonate and is given as an intravenous infusion once yearly. However, the appropriate time to initiate zoledronate treatment after a hip fracture has not yet been established. To clarify the optimal timing of zoledronate to hip fracture patients we have designed a double-blinded, placebo-controlled randomized non-inferiority trial to compare if zoledronate administered early (within 5 days) after hip fracture surgery is as good as zoledronate given late (3 months) after hip fracture surgery.

Timeline

Start
2021-12-15
Primary completion
2026-03-31
Completion
2026-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 5 mg Intravenous

Indications